Skip to content

Esketamine: all studies

Page 25 of 123: studies 241 to 250 of 1,225, newest first. Back to the esketamine overview

Research

Efficacy and acceptability of ketamine and esketamine in adults with treatment-resistant major depressive disorder: systematic review and meta-analysis

Open Science Framework 2026 Annemarie van der Meij, Sotiris Poyiadis, Andrea Cipriani et al. preprint

This preregistration documents an update and extension of a meta-analysis of ketamine and esketamine for adults with treatment-resistant major depressive disorder (TRD). The project is nested within an existing network meta-analysis for TRD (NMA-TRD) project, which has already been fully specified and registered: • Muit et al., BMJ Open 2022 – protocol for a systematic review and network...

Effects of esketamine on postoperative pain, anxiety, depression, sleep, and inflammation in pregnancies undergoing cesarean section: A randomized controlled trial.

PLoS One 2026 Yijun Wang, Xiaolu Lin, Xiang Zou et al.

Postoperative pain is the most notable issue after cesarean section (CS). The contributing factors include hyperalgesia, anxiety, depression, sleep disorders, and inflammation. In this study, we explored the effects of esketamine on pain, hyperalgesia, depression, anxiety, sleep disorders, and inflammation after CS. This randomized, blinded, controlled trial enrolled single-term pregnant women...

Esketamine Enhances the Chemosensitivity of Colorectal Adenocarcinoma Cells to 5-Fluorouracil via AMPK/mTOR/HMMR Signaling Pathway.

Oncology research 2026 Yuerou Feng, Panpan Tong, Shuwen Fu et al.

The efficacy of standard 5-fluorouracil (5-FU) chemotherapy for colorectal cancer is limited by drug resistance and adverse effects, prompting research into esketamine, a potent ketamine variant with analgesic, antidepressant, and recently discovered anti-tumor properties, to determine if it can enhance 5-FU's chemosensitivity. This study investigates whether esketamine synergizes with 5-FU to...

DOI: 10.32604/or.2025.072563 (opens in new tab) Full text (opens in new tab) Esketamine 5-fluorouracil Ampk/mtor/hmmr pathway Chemosensitivity +1

Transcriptional Signatures of Mitochondrial Metabolism Predict Esketamine-Induced rACC Structural Changes in Adolescent Major Depression.

Journal of the American Academy of Child & Adolescent Psychiatry December 31, 2025 Yanling Zhou, Weicheng Li, Xiaofeng Lan et al.

Objective: To investigate neurobiological mechanisms through which esketamine produces rapid antidepressant effects in adolescents with major depressive disorder (MDD), focusing on structural changes in the rostral anterior cingulate cortex (rACC) and associated molecular pathways. Method: A total of 49 adolescents (13-18 years of age) with DSM-5 MDD were randomized to receive intravenous...

DOI: 10.1016/j.jaac.2025.12.011 (opens in new tab) Esketamine Adolescent depression Transcriptomics Mitochondrial metabolism +1

Effectiveness of Intranasal Esketamine on Suicidal Ideation and Depressive Symptoms in Patients with Treatment-Resistant Depression: A Longitudinal Study

Journal of Clinical Medicine December 29, 2025 Matteo Leonardi, Alice Frediani, Mauro Angeletti et al.

Background: Suicidal ideation (SI) represents a clinical challenge in patients with treatment-resistant depression (TRD), and the management of this condition should be as rapid and effective as possible. Intranasal Esketamine has shown promise in patients with TRD due to its rapid onset of action on both SI and depressive symptoms. Since this medication has been recently approved, real-world...

Network pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine

Computational and Structural Biotechnology Journal December 29, 2025 Silvia Tapia-Gonzalez, Josue G. Yagüe, George E. Barreto

Major depressive disorder (MDD) is a multifactorial mental health condition involving genetic, environmental, and neurobiological factors. Conventional antidepressants such as fluoxetine, a selective serotonin reuptake inhibitor, require weeks to exert therapeutic effects, whereas ketamine and esketamine act rapidly via glutamatergic modulation. These drugs may also converge on the inhibition...

The Emerging Role of Ketamine and Esketamine in the Concurrent Management of Pain and Depression in Cancer Patients: Evidence and Implications for Practice

Journal of Pain & Palliative Care Pharmacotherapy December 27, 2025 Shannon Moriarty, Anna Dushenkov, Kathleen M. Frey

Cancer patients frequently experience pain and depression, yet current guidelines address these conditions separately and do not recommend a single agent for concurrent management. Ketamine and its S-enantiomer esketamine, through N-methyl-D-aspartate receptor antagonism and glutamate modulation, may offer dual benefit. This paper examined ten clinical studies published between 2018 and 2024...

A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals

European Journal of Clinical Pharmacology December 22, 2025 Claudia Pisanu, Shungo Imai, Masami Tsuchiya et al. 3 citations

Our results increase knowledge on potential risks related to esketamine AEs and potential drug-drug interaction signals in a real-world setting.

DOI: 10.1007/s00228-025-03954-z (opens in new tab) Full text (opens in new tab) Pharmacovigilance Adverse effect Intensive care medicine Pharmacology +3

Effects of Esketamine on Postoperative Cognitive Function in Elderly Patients Undergoing Pulmonary Lobectomy: A Randomised, Single-Blind Controlled Clinical Trial

Actas Españolas de Psiquiatría December 17, 2025 Xueping Li, Haoping Mao, Jiao Luo et al. 1 citation

BACKGROUND: Elderly patients undergoing pulmonary lobectomy with incision are at a high risk for postoperative cognitive dysfunction (POCD). Intraoperative esketamine may offer potential neuroprotective benefits. This study aimed to evaluate the efficacy of intraoperative esketamine in reducing the incidence of POCD in elderly patients undergoing pulmonary lobectomy with incision. METHODS: In...

DOI: 10.62641/aep.v53i6.2044 (opens in new tab) Clinical trial Cognition Anesthesia Pulmonary function testing

Case Report: A possible association between significant dissociations after esketamine treatment and histrionic personality disorder

Frontiers in Psychiatry December 17, 2025 Veronika Savica, Liene Sīle, Māris Taube 1 citation

Dissociation is a complex and transdiagnostic phenomenon defined as a disruption of, or discontinuity in, the normal, subjective integration of one or more aspects of psychological functioning. Dissociation has been identified as one of the most frequently occurring adverse effects associated with the use of esketamine nasal sprays. Individuals with high trait dissociation may be at a higher...

DOI: 10.3389/fpsyt.2025.1666781 (opens in new tab) Dissociation chemistry Dissociative identity disorder Dissociative disorders Multiple personality disorder +6